What type of study is this?

This is a Systematic Review study (also classified as: Meta-Analysis).

October 16, 2025CureusOpen Access

Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials

View Full Paper

Ask AI

Bookmark

Authors

FFFaizan FazalRawalpindi Medical University MBMuhammad Nauman BashirHoly Family Hospital MAMaham Leeza Adil

Discussion

Member takes

Implication

Systematic review shows higher pathologic complete response rates with pertuzumab in early-stage HER2-positive patients, indicating improved treatment efficacy.

Key Points

The addition of pertuzumab significantly increases pathologic complete response rates in early-stage HER2-positive breast cancer patients.
Results indicated a pathologic complete response rate of 45% in the pertuzumab group compared to 32% in the control group (odds ratio 2.10).
Three double-armed clinical trials with 840 participants were analyzed, assessing the impact of neoadjuvant therapies on treatment outcomes.
Findings suggest incorporating pertuzumab into neoadjuvant therapy could enhance survival rates by improving pathologic complete response.

Cite This Study

Fazal et al. (2025) studied this question.

synapsesocial.com/papers/68f0ba59c50c73ebef9fa8ed https://doi.org/10.7759/cureus.c361

View Full Paper

Ask AI

Bookmark

Implication

Systematic review shows higher pathologic complete response rates with pertuzumab in early-stage HER2-positive patients, indicating improved treatment efficacy.

Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Pathologic Complete Response Achieved in Early-Stage HER2-Positive Breast Cancer After Neoadjuvant Therapy With Trastuzumab and Chemotherapy vs. Trastuzumab, Chemotherapy, and Pertuzumab: A Systematic Review and Meta-Analysis of Clinical Trials

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider